Norway Patent System

Norway is the world's largest producer of Atlantic salmon (accounting for approximately 55–60% of global Atlantic salmon production) and has developed a rich IP ecosystem around aquaculture technology. Norwegian aquaculture IP categories: (1) Sea cage and farming systems: closed containment systems (to reduce sea lice and disease); pen net materials (ultra-high-molecular-weight polyethylene netting — UHMWPE — stronger and lighter than nylon, patented by Norwegian net manufacturers Garware and others); automated feeding systems (underwater feed cameras, feed-stop systems using underwater video AI to detect uneaten pellets); salmon counting systems (laser-based acoustic fish counting); (2) Health and vaccines: MSD Animal Health, Pharmaq (Zoetis Norway), and PHARMAQ Analytiq — Norwegian vaccine companies have developed aquaculture vaccines for ISA (infectious salmon anaemia), IHN, IPN, and salmon lice. Aquaculture vaccines were pioneered in Norway in the 1990s and dramatically reduced antibiotic use in Norwegian salmon farming (from 1 metric ton of antibiotics in 1993 to near zero by 2013 — one of the most dramatic antibiotic reductions in any food animal sector globally); (3) Feed and nutrition: Cargill Aqua Nutrition, BioMar, and Skretting (Nutreco) develop aquafeed formulations with patents in: plant-based protein substitutes for fishmeal; lipid profiles optimized for omega-3 retention; probiotic and prebiotic feed additives; (4) Sea lice control: sea lice (Lepeophtheirus salmonis) are the most commercially damaging parasite in Norwegian salmon farming. Patents in: laser-based sea lice removal systems (Stingray Marine Solutions — StingRay lice laser — commercially deployed); warm water treatment systems (Thermolicer, TermluX — using hot water brief immersion to kill lice); snorkel cages (submerging salmon below lice-infested surface water using submersible cage designs); freshwater treatment systems; hydrogen peroxide bath treatment systems; (5) Genetics and selective breeding: Aqua Gen (salmon genetics and selective breeding company — AquaGen) holds proprietary salmon genetics IP including selective breeding programs; SNP (single nucleotide polymorphism) panels for genomic selection have been developed and patented by Norwegian institutions; CRISPR applications in salmon genetics is an emerging frontier.

Beyond energy and aquaculture, Norway has significant IP activity in defence technology, maritime systems, and digital innovation: (1) Kongsberg Group (Kongsberg — defence, maritime, oil and gas, aerospace): Kongsberg is Norway's most important defence and maritime technology company. Patents in: Naval Strike Missile (NSM) and Joint Strike Missile (JSM) guidance and seeker technology; NASAMS (National Advanced Surface-to-Air Missile System) — used by multiple NATO members and supplied to Ukraine; DP (dynamic positioning) systems for offshore vessels (Kongsberg Maritime); autonomous underwater vehicles (AUVs); fish finding and mapping sonar for aquaculture; radar systems; (2) Vard (Fincantieri subsidiary, Aalesund — specialist vessel design/construction): patents in custom vessel design — LNG-powered offshore vessels, cruise expedition vessels, fish farm service vessels; (3) Yara International (Oslo — world's largest fertilizer company, publicly listed): green ammonia patents (Yara is a major investor in green hydrogen/ammonia production as a fertilizer feedstock and as a shipping fuel; Yara Clean Ammonia — patents in green ammonia synthesis, ammonia fuel cells, ammonia cracking for hydrogen); (4) Nordic Semiconductor (Oslo — Bluetooth and cellular IoT chipsets): Nordic Semi designs low-power wireless chips (nRF52 and nRF91 series) for Bluetooth, BLE, and cellular IoT applications. Holds semiconductor design patents primarily at USPTO, EPO; (5) Tomra Systems (Asker — reverse vending machines for bottle/can deposit return): TOMRA holds patents in optical recognition systems for container sorting, deposit-return machine mechanics, and data analytics for deposit systems; international expansion IP as global container deposit systems expand (Germany, US states, Australia). Digital Norway: Telenor (Oslo — telecom — 5G network patents); Opera (browser IP, sold to Chinese investors 2016 but Norwegian-founded).

Norway is a member of the European Patent Convention (EPC) — meaning the EPO processes Norwegian patent applications and European patents (EP patents) can be validated in Norway — but Norway is NOT a participant in the Unified Patent Court (UPC) Agreement. The reason lies in political status: the EPC is a separate international treaty that any European country can sign, regardless of EU membership. Norway joined the EPC on January 1, 2008. By contrast, the Unified Patent Court Agreement (which created the UPC and the Unitary Patent system) is an EU instrument — it was established under EU law (EU Regulation 1257/2012) and can only include EU member states. Norway, despite being part of the European Economic Area (EEA), is not an EU member state and therefore cannot ratify the UPC Agreement. The same applies to other EPC-member, non-EU countries: Switzerland (EPC member since 1978, not UPC), Iceland (EPC member, not UPC), Liechtenstein (EPC member, not UPC), Turkey (EPC member since 2000, not UPC), North Macedonia, San Marino, Monaco, and Albania. What this means practically: (1) An EPO-granted European patent (EP) must be separately validated in Norway through Patentstyret to take effect in Norway — requiring a Norwegian translation and validation fee. This is the same process as validating an EP in Turkey or Switzerland; (2) A Unitary Patent — the new single patent right automatically effective in all UPC participating EU member states — does NOT cover Norway. Companies cannot rely on a Unitary Patent for Norwegian protection; (3) Disputes about a European patent's validity or infringement in Norway are litigated in Norwegian national courts, not the UPC. A UPC revocation judgment invalidating a European patent has no automatic effect on the Norwegian validation of the same patent.

No — Norway abolished its utility model (petitpatent or bruksmønster) system in 2002. This makes Norway somewhat unusual among European patent systems: most other European patent systems that have utility models have retained them (Germany's Gebrauchsmuster; Denmark's brugsmodel; Finland's hyödyllisyysmalli; Italy's modello di utilità; Spain's modelo de utilidad), while Norway eliminated its utility model entirely. Prior to 2002, Norway had a petitpatent system providing shorter-term, lower-inventive-step protection similar to other European utility models. The decision to abolish it in 2002 was based on assessments that the system was underused and that the standard patent system adequately met Norwegian industry's needs. Consequences for Norwegian applicants and foreign applicants seeking Norway-specific protection: (1) If an invention would qualify for a utility model in Germany or Denmark but fails the inventive step test for a full patent, it CANNOT be registered as a utility model in Norway. The applicant must either secure an invention patent at Patentstyret (by arguing inventive step) or validate an EP patent in Norway if it was granted by the EPO; (2) EPO-granted European patents validated in Norway provide the same effect as a national invention patent — there is no utility model layer in Norway; (3) Companies serving a Nordic market sometimes file utility models in Denmark (brugsmodel, 10yr, lower inventive step) for Danish protection and rely on a validated EP patent for Norwegian protection — the lack of Norwegian utility model does not prevent Nordic IP protection, it just removes a route; (4) The absence of a Norwegian utility model is relevant for technology areas where incremental improvements dominate (aquaculture equipment, offshore systems, industrial machinery) — Norwegian companies in these sectors rely on full patents, trade secrets, or Danish/Finnish utility models for specific innovations.

Equinor ASA (formerly Statoil until 2018, headquartered in Stavanger) is Norway's largest company by revenue and one of the most significant patent filers in the energy sector, with a portfolio spanning offshore oil and gas extraction, carbon capture and storage (CCS), and offshore wind. Equinor's patent strategy reflects its transition from a pure oil company toward an integrated energy company: (1) Offshore oil and gas: Equinor has been instrumental in developing the technology that enables offshore operations in the Norwegian Continental Shelf — one of the world's most technologically demanding offshore environments with deep water (300–400m in some fields), harsh weather, and complex subsea geology. Key patents include subsea production system designs (suction anchors, subsea templates), seismic processing algorithms, and enhanced oil recovery techniques. Equinor licenses some of these technologies to other operators — particularly subsea and floating production technologies; (2) Carbon Capture and Storage (CCS): the Sleipner CCS facility (operational since 1996) was the world's first commercial offshore CCS project. Equinor holds patents and extensive operational know-how in CO2 injection, aquifer storage monitoring, and CO2 compression. The Northern Lights project (a JV with Shell and TotalEnergies) positions Norway as a European hub for carbon storage services — Equinor's CCS IP is commercially valuable as industrial emitters across Europe seek to offset their carbon footprints through geological storage; (3) Floating offshore wind: the Hywind spar-buoy floating wind technology is one of Equinor's most commercially important non-oil IP assets. Hywind Scotland (2017) was the world's first commercial floating offshore wind farm. Equinor licenses the Hywind design to other projects and holds related mooring, dynamic cable, and control system patents; (4) Filing strategy: Equinor files primarily via the EPO for European coverage, with key filings also at USPTO, CNIPA, and Patentstyret for Norwegian national/validation filings. They maintain a professional IP function with both patent attorneys and technical IP staff.

Norway has its own national Supplementary Protection Certificate (SPC) system that operates independently of the EU SPC Regulation 469/2009. Because Norway is not an EU member state, EU regulations do not automatically apply — but Norway has implemented a functionally similar national SPC system that closely mirrors the EU approach. The Norwegian SPC framework: (1) Legal basis: Lov om supplerende beskyttelsessertifikat for legemidler og plantevernmidler (1994, as amended) — Norway's own SPC Act. The Norwegian SPC system was intentionally aligned with the EU SPC Regulation through EEA law implementation (Norway adopts much EU pharmaceutical regulatory law through the EEA Agreement); (2) Products covered: pharmaceutical products and plant protection products (same as EU SPC Regulation). An SPC can be obtained for an active ingredient or combination of active ingredients in a medicinal product or plant protection product; (3) Requirements: a valid patent must exist for the product or process; a marketing authorization from the Norwegian Medicines Agency (Statens legemiddelverk, or Legemiddelverket) must exist for the product in Norway; the marketing authorization must be the first authorization in Norway for the product as a medicinal product; (4) Duration: maximum 5 years extension beyond the 20-year patent term. Plus the possibility of a 6-month pediatric extension (Norway has implemented a national pediatric extension equivalent to EU Regulation 1901/2006); (5) Relationship to EU SPCs: EU SPCs are NOT automatically valid in Norway. A drug company that obtains an EU SPC for a product in France or Germany does not automatically have SPC protection in Norway. A separate Norwegian SPC application must be filed with Patentstyret based on the Norwegian marketing authorization. However, Norwegian courts and Patentstyret generally look to CJEU (Court of Justice of the European Union) case law on SPC interpretation when interpreting the Norwegian SPC Act because the Acts are substantively similar — this creates substantial de facto alignment between Norwegian and EU SPC practices.

Norwegian salmon aquaculture — producing approximately 55–60% of the world's farmed Atlantic salmon — has generated a distinctive and commercially valuable patent ecosystem that reflects Norway's unique position in global food production. Key features of Norwegian aquaculture IP: (1) Sea lice as the primary patent driver: Lepeophtheirus salmonis (Atlantic salmon louse) causes billions of dollars in annual losses to the Norwegian salmon industry and is the single most intensely-researched problem in aquaculture. The resulting IP landscape is dense: laser systems (Stingray Marine Solutions' StingRay laser targets individual lice on salmon using vision systems and lasers; patent-protected technology with $100M+ revenue); thermal treatments (Thermolicer — brief hot water immersion, kills lice without harming fish; Hydrolicer — freshwater treatment system); snorkel cages (Norwegian-invented design where a submerged surface barrier forces salmon to swim below the lice-infested surface layer); lice-resistant salmon genetics (AquaGen genomic selection programs); bath treatments using hydrogen peroxide, azamethiphos, and other compounds. This creates a patent enforcement environment where licensing disputes between equipment manufacturers are commercially significant; (2) Closed containment systems: as Norway faces regulatory pressure to reduce wild salmon impact from escaped farmed salmon and sea lice transmission, there is substantial patent activity in closed and semi-closed containment systems (land-based recirculating aquaculture systems [RAS], submerged cages, flow-through systems); (3) Feed innovation: Norway has developed a major aquafeed technology sector (Cargill Aqua Nutrition in Bergen; BioMar in Brande, Denmark but Norwegian market; Skretting/Nutreco) with patents in plant-protein substitution for fishmeal (using soy protein concentrate, insect meal, single-cell protein), omega-3 conversion efficiency (reducing the use of wild-caught forage fish), and precision feeding automation; (4) Genetic IP: AquaGen (founded from former Norwegian aquaculture research) holds proprietary selective breeding programs for salmon — disease resistance, growth rate, fillet quality traits — protected through trade secrets and, increasingly, patents on genomic markers and CRISPR-based gene editing approaches.